Literature DB >> 209809

Peripheral neuropathy related to misonidazole: incidence and pathology.

R C Urtasun, J D Chapman, M L Feldstein, R P Band, H R Rabin, A F Wilson, B Marynowski, E Starreveld, T Shnitka.   

Abstract

The human tolerance to multiple dosages of misonidazole (Ro-07-0582) was studied in 28 patients with different types of malignant neoplasias. The mean total dose for this group of patients was 16.2 g. The main toxicity was peripheral neuropathy with an overall incidence of 35%. This neuropathy occurred more frequently and with greater severity when the drug was administered 3 times a week and when patients received total doses of over 18 g. The best tolerated schedule appears to be once or twice a week up to total dosages of 18 g or less (approximately 11 g/m2). Electron microscopy of a sural nerve biopsy from an affected patient revealed residual of previous distal axonal degeneration, with some segmental demyelination and remyelination, which affected both large and small myelinated nerve fibres.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209809      PMCID: PMC2149411     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  6 in total

1.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

Review 2.  Peripheral neuropathy caused by chemical agents.

Authors:  J B Cavanagh
Journal:  CRC Crit Rev Toxicol       Date:  1973-11

3.  Letter: "High-dose" metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials.

Authors:  R C Urtasun; J Sturmwind; H Rabin; P R Band; J D Chapman
Journal:  Br J Radiol       Date:  1974-05       Impact factor: 3.039

4.  Letter: Metronidazole and tissue zinc/iron ratio in cancer therapy.

Authors:  R L Willson
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

5.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

6.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

  6 in total
  25 in total

1.  Misonidazole neuropathy. A prospective study.

Authors:  B Melgaard; O Køhler; H Sand Hansen; J Overgaard; J Munck-Hansen; O B Paulson
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

2.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study.

Authors:  Sydney M Evans; Kevin W Jenkins; H Isaac Chen; W Timothy Jenkins; Kevin D Judy; Wei-Ting Hwang; Robert A Lustig; Alexander R Judkins; M Sean Grady; Stephen M Hahn; Cameron J Koch
Journal:  Transl Oncol       Date:  2010-06-01       Impact factor: 4.243

4.  Evoked potentials in rats with misonidazole neurotoxicity. I. Brain stem auditory evoked potentials.

Authors:  M S Edwards; S K Powers; R A Baringer; D L Jewett; C Bolger; T L Phillips
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

5.  Plasma concentrations and pharmacokinetics of misonidazole after intraperitoneal administration to the mouse.

Authors:  M F Malmary-Nebot; C Labat; M Terrissol; B Martin; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

6.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Misonidazole neurotoxicity in rats: Part I. Evaluation of misonidazole neurotoxicity in rats by analysis of brain stem auditory and cortical evoked potentials.

Authors:  M S Edwards; D G Gordon; V A Levin; T L Phillips
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

8.  Misonidazole neurotoxicity in rats: Part II. Effect of pre- and intermittent treatment with pentobarbital on misonidazole neurotoxicity in the rat.

Authors:  M S Edwards; D G Gordon; A Salamy; V A Levin; T L Phillips
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors.

Authors:  Sydney M Evans; Kevin W Jenkins; W Timothy Jenkins; Thomas Dilling; Kevin D Judy; Amy Schrlau; Alexander Judkins; Stephen M Hahn; Cameron J Koch
Journal:  Radiat Res       Date:  2008-12       Impact factor: 2.841

10.  Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.

Authors:  G Akel; P Benard; P Canal; G Soula
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.